NCT05307978View on ClinicalTrials.gov

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

February 7, 2023

Study Completion Date

February 7, 2023

Conditions
Healthy
Interventions
DRUG

ALXN1910

Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.

DRUG

Placebo

Participants will receive Placebo IV or Placebo SC according to their assigned cohort.

Trial Locations (1)

HA1 3UJ

Clinical Trial Site, Harrow

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY